NanoViricides, Inc. (NanoViricides, Inc. (NYSE American: NNVC)) reported financial results for its fiscal year ended June 30, 2026, showcasing progress in its antiviral drug development and improved cash reserves. The company received regulatory approval in the Democratic Republic of Congo for Phase II trials of its broad-spectrum antiviral candidate NV-387 Oral Gummies for the treatment of Mpox and Ebola, with enrollment beginning at the end of September 2026. Additionally, the U.S. Food and Drug Administration granted Orphan Drug Designation and Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles.
Financially, NanoViricides ended the fiscal year with approximately $2.79 million in cash and cash equivalents, up from $1.67 million a year earlier. The company raised approximately $9.01 million through registered direct and at-the-market equity offerings during fiscal 2026, and subsequently raised an additional $3.8 million in July. It is pursuing further funding through grants, contracts, partnerships, and debt or equity financing. For a detailed view of the full press release, visit https://ibn.fm/s000r.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide™ class of drug candidates is based on intellectual property and technology from TheraCour Pharma, Inc. The lead candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. Another advanced candidate, NV-HHV-1, targets Shingles. The company’s business model relies on licensing technology from TheraCour for specific viral applications, established at its founding in 2005. More information is available at www.nanoviricides.com.
The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. MissionIR, a specialized communications platform, distributed this announcement. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
The advancement of NV-387 into Phase II trials for Mpox and Ebola marks a critical step for NanoViricides, as these viral diseases lack effective broad-spectrum treatments. The FDA designations for measles further validate the drug’s potential. With increased cash reserves and ongoing fundraising efforts, the company is positioned to continue its clinical programs. However, as with any drug development, there can be no assurance that the candidates will show sufficient effectiveness and safety for human clinical development. The path to typical drug development is extremely lengthy and requires substantial capital.
